Missouri collects $2.5M OxyContin settlement

Missouri has become the latest state to collect on a $160 million legal settlement between OxyContin maker Purdue Pharma, the federal government and 26 state Medicaid programs. Purdue was settling claims that it marketed OxyContin improperly by using false claims. In this case, Purdue paid Missouri $5.9 million to its Medicaid program. More than half, about $3.4 million, went to the federal government to reimburse it for its share of Medicaid funding, but the remaining $2.5 million went to the state.

To learn more about the settlement:
- read this St. Louis Business Journal item

Related Articles:
IFMPA institutes new pharma marketing rules. Report
Henry Ford bans pharma perks, vendor drop-ins. Report
A flight of pharma marketing fancy. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.